Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

In the first quarter, the Frito-Lay maker posted its first quarterly profit miss in at least five years. PepsiCo's revenue ...

Many Wall Street analysts keep boosting their stock price target as the streaming giant's shares have gained around 40 ...

Netflix had success with "Squid Game" in the second quarter, but investors and analysts want to know what's next outside the ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of ...

Our Top 5 Analyst Questions Pfizer’s Q1 Earnings Call Vamil Divan (Guggenheim): Asked about Pfizer’s ability to maintain and grow its dividend amid tariff uncertainty and cash flow pressure.

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential 29% upside. Click here to read.

Pfizer: Competitive Advantages Still Exist, but Signs of Erosion Lead Us to Lower Our Valuation We’ve also reduced the firm’s moat rating from wide to narrow.

Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.